Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study
Erberto Carluccio, Frank Lloyd Dini, Roberto Bitto, et al.
International Journal of Cardiology (2022) Vol. 350, pp. 62-68
Closed Access | Times Cited: 19

Showing 19 citing articles:

Sacubitril/valsartan in a wide spectrum of heart failure patients (from mechanisms of action to outcomes in specific populations)
Przemyslaw Rajzer, Jan Biegus
Heart Failure Reviews (2025)
Open Access | Times Cited: 1
The history and mystery of sacubitril/valsartan: From clinical trial to the real world
Mingsong Zhang, Yifei Zou, Yangxue Li, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 12
Evaluation of the 6-Month Effect of Sacubitril-Valsartan Compared to ACEI and ARB on LVEF in Heart Failure Patients: A Double-Blind Randomized Clinical Trial
Farnosh Masmoo, Farnaz Fariba, Nakisa Khansari, et al.
Journal of Pharmacy And Bioallied Sciences (2025)
Open Access
Effect of sacubitril/valsartan on cardiac remodeling compared with other renin–angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples
Erberto Carluccio, Frank Lloyd Dini, Michele Correale, et al.
Clinical Research in Cardiology (2023) Vol. 113, Iss. 6, pp. 856-865
Open Access | Times Cited: 9
Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study)
Andrea Di Lenarda, Gabriele Di Gesaro, Filippo M. Sarullo, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 2, pp. 699-699
Open Access | Times Cited: 8
The Long-Term Benefit of Sacubitril/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population
Giuseppe Dattilo, Giulia Laterra, Roberto Licordari, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 19, pp. 6247-6247
Open Access | Times Cited: 7
Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study
Mauro Acquaro, Laura Scelsi, Beatrice Pasotti, et al.
Vascular Pharmacology (2023) Vol. 152, pp. 107196-107196
Closed Access | Times Cited: 5
Prediction of recurrent heart failure hospitalizations and mortality using the echocardiographic Killip score
Yoav Granot, Y. J. Meir, Michal Laufer Perl, et al.
Clinical Research in Cardiology (2024)
Open Access | Times Cited: 1
Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure
Taha Mansoor, Subaina N. Khalid, Muhammad Ibraiz Bilal, et al.
American Journal of Cardiovascular Drugs (2024) Vol. 24, Iss. 4, pp. 481-504
Closed Access | Times Cited: 1
Effects of sacubitril/valsartan on both metabolic parameters and insulin resistance in prediabetic non-obese patients with heart failure and reduced ejection fraction
C Cloro, Isabella Zaffina, Luca Sacchetta, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 7
Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan
Iacopo Fabiani, Nicola Riccardo Pugliese, Gianni Pedrizzetti, et al.
ESC Heart Failure (2023) Vol. 10, Iss. 5, pp. 2927-2938
Open Access | Times Cited: 3
Effect of Sacubitril-Valsartan on Restoration and Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation
Qingsong Chen, Yunlin Chen, Fang Qin, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 5
Irreversible myocardial injury attenuates the benefits of sacubitril/valsartan in heart failure patients
Hong‐Mi Choi, In‐Chang Hwang, Hye Jung Choi, et al.
International Journal of Cardiology (2023) Vol. 397, pp. 131611-131611
Closed Access | Times Cited: 2
Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure
Sheldon E. Litwin, Cara East
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 4
New guidelines for managing chronic heart failure patients and new needs in echocardiography
Erwan Donal, G L'official, Wojciech Kosmala
International Journal of Cardiology (2022) Vol. 353, pp. 71-72
Open Access | Times Cited: 3
Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registry
Lars H. Lund, Uwe Zeymer, Andrew L. Clark, et al.
International Journal of Cardiology (2022) Vol. 370, pp. 279-286
Closed Access | Times Cited: 3
Vericiguat in heart failure with reduced ejection fraction: hope or solid reality?
Michele Correale, Giuseppe Pelaggi, Maria Concetta Catanoso, et al.
Heart Failure Reviews (2024) Vol. 29, Iss. 5, pp. 1135-1143
Closed Access
Patient phenotype profiling using echocardiography and natriuretic peptides to personalise heart failure therapy
Frank Lloyd Dini, Erberto Carluccio, Stefano Ghio, et al.
Heart Failure Reviews (2023) Vol. 29, Iss. 2, pp. 367-378
Closed Access | Times Cited: 1
Unveiling Wide Spectrum Therapeutic Implications and Signaling Mechanisms of Valsartan in Diverse Disorders: A Comprehensive Review
Kuldeep Kumar, Pooja Rawat, Simrat Kaur, et al.
Current Drug Research Reviews (2023) Vol. 16, Iss. 3, pp. 268-288
Closed Access
Page 1

Scroll to top